Interferon alpha-2a biosimilar - Biolotus

Drug Profile

Interferon alpha-2a biosimilar - Biolotus

Alternative Names: INTEFEN-IFN

Latest Information Update: 01 Jul 2015

Price : $50

At a glance

  • Originator Biolotus
  • Developer Biolotus; Shenyang Sunshine Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata; Haematological malignancies; Hepatitis B; Hepatitis C; Lymphoma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 19 Jun 2015 Launched for Lymphoma, Hepatitis B, Hepatitis C, Hematological malignancies and Condylomata acuminata in Brazil (IM) (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top